Earnings report 📈 Stocks 🌍 United States

Xtant Medical Swings to $3.6M Loss, Withdraws 2026 Guidance Amid Review

Xtant Medical shares face pressure as the company reports a $3.6 million Q3 loss, misses guidance for the second straight quarter, and launches a broad strategic review of its operations and capital structure.

🕐 1 min read

1 assets impacted. Net bias: 0 Bullish, 1 Bearish, 0 Neutral. Strongest signal: XTNT ↓ 7/10 (75% confidence).

📊 Affected Assets (1)

XTNT
Bearish 🤖 75%
📅 Short-term 🌍 US · Explicit

Xtant reported its second consecutive quarter missing guidance, withdrew full-year 2026 guidance, swung to a $3.6 million net loss from a $1.3 million profit a year earlier, and saw revenue fall to $24.3 million from $33.3 million. Gross margin dropped to 56.3% from 66.1% and cash fell to $7.8 million from $17.1 million. The board-led strategic review offers possible speculative upside, but the hard fundamentals are negative.

Catalysts
  • ▼ Second consecutive quarter missing guidance and full-year 2026 guidance withdrawn
  • ▼ Net loss of $3.6 million ($0.03/share) vs net income of $1.3 million in Q3 2025
Risk Factors
  • ▲ Biologics revenue grew 13% year-over-year to $19.3 million, including $2.2 million from HEMOBLAST Bellows
  • ▲ Strategic review could produce a value-maximizing transaction, though no timetable or assurance of outcome is given

🎯 Key Takeaways

  • Net loss reached $3.6 million in Q3 2026, compared to a $1.3 million profit in Q3 2025.
  • Total revenue fell to $24.3 million from $33.3 million in the year-ago period.
  • Gross margin declined to 56.3% from 66.1% in Q3 2025.
  • Cash and cash equivalents dropped to $7.8 million as of September 30, 2026, down from $17.1 million at year-end 2025.
  • Biologics revenue grew 13% year-over-year to $19.3 million, including $2.2 million from HEMOBLAST Bellows.

📝 Executive Summary

Xtant Medical Holdings reported a $3.6 million net loss for the third quarter of 2026, marking its second consecutive quarter missing financial guidance. Consequently, the company has withdrawn its full-year 2026 outlook and initiated a board-led strategic review to explore potential partnerships, financings, or business combinations to maximize stockholder value.

❓ FAQ

Why is the stock likely to fall on this news?

The company missed its guidance for the second quarter in a row, withdrew its full-year 2026 guidance, and reported a $3.6 million net loss versus a $1.3 million profit a year ago, with revenue down to $24.3 million from $33.3 million.

Could the strategic review lift the stock instead?

The board is reviewing alternatives such as partnerships, financings, acquisitions or dispositions to maximize stockholder value, but it set no timetable and said there is no assurance of any action, so this is speculative rather than a concrete positive.